activity
20212025
most citedBeyond the classical type I error: Bayesian metrics for Bayesian designs using informative priors

2 citations · 3 across the 4 of their papers we have counts for

collaborators

5 papers

stat.ME2025★ 1 cited

On the interplay between prior weight and variance of the robustification component in Robust Mixture Prior Bayesian Dynamic Borrowing approach

Marco Ratta, Gaelle Saint-Hilary, Mauro Gasparini +1

Robust Mixture Prior (RMP) is a popular Bayesian dynamic borrowing method, which combines an informative historical distribution with a less informative component (referred as robu…

stat.ME2023★ 2 cited

Beyond the classical type I error: Bayesian metrics for Bayesian designs using informative priors

Nicky Best, Maxine Ajimi, Beat Neuenschwander +2

There is growing interest in Bayesian clinical trial designs with informative prior distributions, e.g. for extrapolation of adult data to pediatrics, or use of external controls.…

stat.AP2022

Implementation and pratical aspects of quantitative decision-making in clinical drug development

Juan J. Abellan, Nicolas Bonnet, Alex Carlton +7

Quantitative decision-making (QDM) principles address the issues related to the mapping of results to decisions, the synthesis of information and the quantification of uncertainty.…

stat.ME2021

A Comparison of Various Aggregation Functions in Multi-Criteria Decision Analysis for Drug Benefit-Risk Assessment

Tom Menzies, Gaelle Saint-Hilary, Pavel Mozgunov

Multi-criteria decision analysis (MCDA) is a quantitative approach to the drug benefit-risk assessment (BRA) which allows for consistent comparisons by summarising all benefits and…

stat.ME2021

A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies

Helen Yvette Barnett, Matthew George, Donia Skanji +3

It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the ri…